Akeso and Summit Report P-III (HARMONi-GI1) Trial Data on Ivonescimab + CT for 1L Advanced Biliary Tract Cancer

Shots: Akeso and Summit have reported interim analysis from the P-III (AK112-309/HARMONi-GI1) trial assessing ivonescimab + CT vs durvalumab + CT for the 1L treatment of advanced biliary tract cancer (BTC) Trial met its 1EP of OS, plus achieved all key 2EPs of PFS & ORR; data will be presented at the academic conference & published…

ByRidhi RastogiAugust 26, 2026

Summit and Akeso Reports NMPA Approval for Ivonescimab + CT for 1L Squamous NSCLC

Shots: Chinese NMPA has approved ivonescimab + CT for the 1L treatment of pts with advanced squamous NSCLC (sqNSCLC), based on the global P-III (HARMONi-6) trial The trial, sponsored by Akeso, assessed ivonescimab + CT vs Tevimbra + CT to treat Chinese pts with 1L sqNSCLC irrespective of PD-L1 expression, showing improved OS & PFS;…

ByRidhi RastogiAugust 13, 2026

Akeso Presents the P-III (HARMONi-6) Trial Data on Ivonescimab + CT in 1L Squamous NSCLC at ASCO 2026

Shots: The Akeso's global P-III (HARMONi-6/AK112-306) trial assessed ivonescimab + CT vs Tevimbra + CT to treat pts (n=532) with 1L sqNSCLC, meeting its 2EP of improved OS As of Feb 27, 2026 (mFU: 21.36mos.), ivonescimab + CT reduced the death risk by 34%(mOS: 27.9 vs 23.7mos.), with 12 and 24mos. OS rate of 78.9%…

ByRidhi RastogiJune 1, 2026

Akeso and Summit Report P-III (HARMONi-GI1) Trial Data on Ivonescimab + CT for 1L Advanced Biliary Tract Cancer

Summit and Akeso Reports NMPA Approval for Ivonescimab + CT for 1L Squamous NSCLC

Akeso Presents the P-III (HARMONi-6) Trial Data on Ivonescimab + CT in 1L Squamous NSCLC at ASCO 2026

Contact US

FOLLOW US